i
Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016
-
April 18, 2016, Update (May 23, 2018)
-
[PDF-1.13 MB]
Details:
-
Personal Author:
-
Description:From the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
The purpose of these guidelines is to provide health care providers in the United States with updated guidelines to the 2005 U.S. Department of Health and Human Services nonoccupational postexposure prophylaxis (nPEP) recommendation1 on the use of antiretroviral nPEP and other aspects of case management for persons with isolated exposure outside health care settings to blood, genital secretions, or other potentially infectious body fluids that might contain human immunodeficiency virus (HIV). The use of occupational PEP (oPEP) for case management for persons with possible HIV exposures occurring in health care settings are not addressed in this guideline; updated oPEP guidelines have been published separately.
This update incorporates additional evidence regarding use of nonoccupational postexposure prophylaxis (nPEP) from animal studies, human observational studies, and consideration of new antiretroviral medications that were approved since the 2005 guidelines, some of which have improved tolerability. New features are inclusion of guidelines for the use of rapid antigen/antibody (Ag/Ab) combination HIV tests, for revised preferred and alternative 3-drug antiretroviral nPEP regimens, an updated schedule of laboratory evaluations of source and exposed persons, updated antimicrobial regimens for prophylaxis of sexually transmitted infections and hepatitis, and a suggested procedure for transitioning patients between nPEP and HIV preexposure prophylaxis (PrEP), as appropriate.
Running title: 2016 nPEP Guidelines Update
-
Content Notes:Curatorial Note: The PDF attached to this record as of 2024-05-08 is a slight revision over the original file first added on 2016-04-13. At the request of the NCHHSTP, the publisher of the Guidelines, Stacks staff made a minor change to the cover of the PDF. Stacks staff removed the text "Update: Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP). Please see attached file." NCHHSTP staff felt the information was no longer valid as dolutegravir is among the preferred drugs for ARV regimens for pregnant women. NCHHSTP staff did not want this outdated information to cause confusion. Stacks staff made no other changes to the intellectual content of the file. If you have questions about this action, you may contact CDC Stacks.
-
Subjects:
-
Document Type:
-
Genre:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
